Publisher Correction: Enhancing therapeutic efficacy: sustained delivery of 5-fluorouracil (5-FU) via thiolated chitosan nanoparticles targeting CD44 in triple-negative breast cancer.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Works by Jahan, Faryal
Results: 6
1
2
Enhancing therapeutic efficacy: sustained delivery of 5-fluorouracil (5-FU) via thiolated chitosan nanoparticles targeting CD44 in triple-negative breast cancer.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-55900-1
- By:
- Publication type:
- Article
3
Enhancing therapeutic efficacy: sustained delivery of 5-fluorouracil (5-FU) via thiolated chitosan nanoparticles targeting CD44 in triple-negative breast cancer.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-55900-1
- By:
- Publication type:
- Article
4
HPLC method development and validation for in vitro and in vivo quantification of vancomycin in rabbit plasma.
- Published in:
- Pakistan Journal of Pharmaceutical Sciences, 2022, v. 35, p. 1683, doi. 10.36721/PJPS.2022.35.6.SP.1683-1690.1
- By:
- Publication type:
- Article
5
Development of mucoadhesive thiomeric chitosan nanoparticles for the targeted ocular delivery of vancomycin against Staphylococcus aureus resistant strains.
- Published in:
- Nanofabrication (2299-680X), 2021, v. 6, n. 1, p. 16, doi. 10.1515/nanofab-2020-0105
- By:
- Publication type:
- Article
6
Association of SLCO1B1 gene variants with angiotensin-converting enzyme inhibitor-induced cough in a Pakistani hypertensive cohort.
- Published in:
- Frontiers in Pharmacology, 2024, p. 01, doi. 10.3389/fphar.2024.1441251
- By:
- Publication type:
- Article